Oxford Biomedica Plc is a Pharmaceuticals company based in the United Kingdom with a medium risk ESG score of 23.1. Specializing in immunotherapy, this biopharmaceutical firm focuses on developing gene-based medicines. Operating in two segments - Platform and Product, the company generates the majority of its revenue from its bioprocessing and process development activities. With a strong presence in Europe, Oxford Biomedica Plc is a key player in the healthcare market.